Kristie L. Kahl

Articles

Hormonal Agents Induce Improved OS in African Americans With Chemo-Naive mCRPC

February 12th 2019

African-American men with metastatic castration-resistant prostate cancer treated with novel hormonal therapies—namely abiraterone acetate or enzalutamide—lived 20% longer than their Caucasian counterparts.

FDA Delays Decision on Frontline Pembrolizumab sBLA in NSCLC

December 21st 2018

The FDA has extended the review period for a supplemental biologics license application for single-agent pembrolizumab for the frontline treatment of patients with locally advanced or metastatic nonsquamous or squamous non–small cell lung cancer with a PD-L1 expression level of ≥1% and no EGFR or ALK genomic tumor aberrations.

Oxybutynin Decreases Hot Flashes, Improves Quality of Life in Breast Cancer Survivors

December 7th 2018

Oxybutynin helped to reduce the frequency and intensity of hot flashes among women who could not take hormone replacement therapy in survivorship.

Association Between pCR and Neoadjuvant Chemo Shows Improved Breast Cancer Outcomes

December 6th 2018

Pathologic complete response following neoadjuvant chemotherapy appeared to be associated with improved survival outcomes among patients with breast cancer.

FDA Grants Atezolizumab Regimen Priority Review for Frontline SCLC

December 5th 2018

The FDA has granted a priority review designation to a supplemental biologics license application for atezolizumab for use in combination with carboplatin and etoposide for the frontline treatment of patients with extensive-stage small cell lung cancer.

Rivaroxaban May Reduce Blood Clot Risk During Active Systemic Cancer Therapy

December 4th 2018

Rivaroxaban may significantly reduce venous thromboembolism occurrence among patients actively being treated with systemic therapy, according to results from the phase IIIb CASSINI trial.

New Prediction Model Improves Personalized Insight Into MDS Survival

December 3rd 2018

An approach using machine learning to analyze genomic and clinical data from patients with myelodysplastic syndromes could replace the gold standard of predicting how long patients may live with the disease.

Beat AML Trial Proves Feasibility of Rapid Treatment Assignment Following Diagnosis

December 3rd 2018

Initial findings from the Beat AML study showed that rapid genetic testing in patients with AML was feasible and helpful, and that a precision medicine approach is possible for these patients, who must be treated urgently given the disease’s rapid progression.

First HCT Following CAR T-Cell Therapy Reduces Risk for ALL Relapse

December 2nd 2018

Receiving a stem cell transplant for the first time following CD19 CAR T-cell therapy induced a reduction in the risk for acute lymphoblastic leukemia (ALL) recurrence, according to a retrospective analysis of the phase I/II PLAT-02 study.

Luspatercept Reduces Blood Transfusion Dependence in Lower-Risk MDS Anemia

December 2nd 2018

Treatment with luspatercept significantly reduced the need for frequent red blood cell transfusions in nearly 53% of patients with anemia associated with low- to intermediate-risk myelodysplastic syndrome.

Lurbinectedin Combo Induces Clinical Activity in Chemo-Sensitive SCLC

September 26th 2018

Lurbinectedin plus doxorubicin demonstrated significant clinical activity as a second-line therapy for patients with small cell lung cancer, especially when excluding refractory patients.

Entinostat/Pembrolizumab Combo Shows Promise in NSCLC Subgroup

September 26th 2018

Ongoing analyses suggest enhanced clinical benefit is derived from the combined use of entinostat and pembrolizumab in a subgroup of patients with PD-1/PD-L1–refractory non–small cell lung cancer who have high levels of peripheral blood monocytes.

Atezolizumab Prolongs Survival in SCLC

September 26th 2018

The addition of atezolizumab to standard carboplatin and etoposide in the frontline setting significantly prolonged survival in patients with extensive-stage small cell lung cancer compared with the chemotherapy regimen alone.

Brigatinib Bests Standard of Care to Improve PFS in Advanced NSCLC

September 25th 2018

Brigatinib reduced the risk of disease progression or death by more than 50% compared to crizotinib in adult patients with ALK-positive, locally advanced or metastatic NSCLC.

Adding Durvalumab to Chemoradiation Improves OS in Unresectable Stage III NSCLC

September 25th 2018

Durvalumab induced a clinically meaningful improvement in overall survival compared with placebo in patients with stage III, unresectable non–small cell lung cancer who have not progressed following chemoradiotherapy.

Atezolizumab Regimen Improves PFS in Frontline Nonsquamous NSCLC

September 25th 2018

The addition of atezolizumab to carboplatin/cisplatin in the first-line setting and to pemetrexed as maintenance therapy significantly improved progression free survival in patients with stage IV nonsquamous NSCLC.

Repotrectinib Shows Promising Activity in ROS1+ NSCLC

September 25th 2018

Repotrectinib (TPX-0005) demonstrates a clinically meaningful and durable benefit across multiple doses in patients with ROS1 fusion–positive NSCLC.

Poziotinib Shows Encouraging Activity Among Heavily Pretreated NSCLC Subgroup

September 25th 2018

Poziotinib demonstrated high antitumor activity in patients with metastatic, heavily pretreated EGFR and HER2 exon 20 mutant non–small cell lung cancer.

FDA Grants Frontline Pembrolizumab Priority Review for Lower PD-L1 Cutoff in NSCLC

September 12th 2018

The FDA has granted a priority review designation to single-agent pembrolizumab for the frontline treatment of patients with locally advanced or metastatic nonsquamous or squamous non–small cell lung cancer with PD-L1 expression ≥1% and no EGFR or ALK genomic tumor aberrations.

Heated Chemo During Resection Shows No Benefit in Advanced CRC

June 4th 2018

The addition of heated chemotherapy delivered to the abdomen during surgery delivered no survival benefit to patients with peritoneal carcinomatosis.